Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KTX-475
- Development stage
- Unknown
- Lead developer
- Kymera Therapeutics
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01
Overview
KTX-475 is an investigational **targeted protein degrader** developed by Kymera Therapeutics as part of its preclinical IRAKIMiD program for **MYD88-mutant diffuse large B-cell lymphoma** and related B-cell malignancies. Available company and conference materials describe it as a heterobifunctional small-molecule degrader that promotes degradation of **interleukin-1 receptor-associated kinase 4** and also degrades **immunomodulatory imide drug substrates**, producing apoptosis and stronger cytotoxic activity in MYD88-mutant DLBCL models than IRAK4 kinase inhibition alone. The program appears to have remained preclinical and is not part of Kymera's current visible clinical pipeline.
02
Targets
CRBN (Cereblon)IKZF1 (Ikaros family zinc finger protein 1)IKZF3 (Zinc finger protein Aiolos)IRAK4 (Interleukin-1 receptor associated kinase 4)
Beyond the preview
Go deeper on KTX-475.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KTX-475.